Efficacy of Gnrh Antagonist Usage in Infertility Patients with Policystic Ovary Syndrome during IUI Cycles

Yıl 2017, Cilt: 6 Sayı: 3, 107 - 113, 01.09.2017

Yeliz Akpınar Mayir Lütfiye Eren Yazıcı Neslihan Erkal Münire Erman Akar

https://doi.org/10.5505/abantmedj.2017.81488

Öz

INTRODUCTION: Polycystic ovary syndrome goes with menstruel irregularity and infertility due to anovulation. In this study, we investigate usage of gonadotropin releasing hormone antagonist for intrauterine insemination cycles among infertile polycystic ovary syndrome patients and also effect of treatment on follicular growth, treatment duration, pregnancy rates. METHODS: 54 patients with polycystic ovary syndrome were included in study, ages between 20-35 years. Patients were divided into two groups. At first group, intrauterine insemination was applied after hCG injection following ovulation stimulation with low dose step up regimen with recombinant FSH and GnRH antagonist application Group 1, n: 27 . At control group ovulation stimulation with same regimen and insemination applied except for GnRH antagonist usage Group 2, n: 27 .RESULTS: In group 2, two patients were excluded from study because of cancellation of cycle due to premature LH increase. Premature increasement in LH levels wasn’t observed in group 2. Monofollicular growth rate was higher in group 1 at end of treatment. Dominant follicular amount and estradiol levels were lower in group 1. Pregnancy rates were 33% and 16% among group 1 and group 2 respectively. DISCUSSION AND CONCLUSION: Premature increasement of LH levels causes cancellation of ovulation induction cycles especially among patients with polycystic ovary syndrome. Expanding usage of GnRH antagonist among insemination cycles can increase pregnancy rates via reducing prematüre LH increase frequency

Anahtar Kelimeler

Polycystic ovary syndrome, infertility, GnRH antagonist

Polikistik Over Sendromlu Infertil Hastalarda IUI Sikluslarında Gnrh Antagonisti Kullanımının Etkinliği

Öz

GİRİŞ ve AMAÇ: Polikistik over sendromu anovulasyon ile ilişkili olarak infertilite ve menstrüel disfonksiyona yol açan bir hastalıktır. Bu çalışmada polikistik over sendromlu infertil hastalarda intrauterin inseminasyon siklusunda gonadotropin salgılatıcı hormon antagonisti kullanımının folliküler gelişim, tedavi süresi ve gebelik oranları üzerine etkisi araştırılmıştır. YÖNTEM ve GEREÇLER: Çalışmaya 20-35 yaş arası polikistik over sendromu olan infertil 54 hasta dahil edildi. Hastalar iki gruba ayrıldı. İlk gruba düşük doz basamaklı artım rejimi ile rekombinant FSH ve GnRH antagonisti kullanılarak ovulasyon indüksiyonu sonrası human koryonik gonadotropin uygulamasını takiben intrauterin inseminasyon yapılan hastalar dahil edildi Grup 1, n: 27 . Kontrol grubunda aynı protokol ile ovaryan stimülasyon ve inseminasyon yapılan ancak GnRH antagonisti kullanılmayan hastalar dahil edildi Grup 2, n: 27 . BULGULAR: Grup 2’deki iki hastada tedavi sırasında gelişen prematür LH artışı nedeniyle sikluslar iptal edildi ve bu iki hasta çalışma dışı bırakıldı. Grup 1’de hiçbir hastada prematür LH artışı izlenmedi. Tedavi sonunda grup 1’de daha fazla hastada monofoliküler gelişim saptandı. Grup 1’de grup 2’ye göre dominant folikül sayısı ve E2 oranı daha düşük idi. Grup 1’de hastaların % 33’ünde 9/27 , grup 2’de ise % 16’sında 4/25 gebelik tespit edildi. TARTIŞMA ve SONUÇ: İVF sikluslarında kullanımı gün geçtikçe artan GnRH antagonisti sayesinde ovulasyon indüksiyonu sonrası planlanan inseminasyon sikluslarında özellikle PKOS’li hastalarda izlenen ve siklus iptallerine neden olan prematür LH artışının da önüne geçilebilir ve gebelik oranları arttırılabilir.

Anahtar Kelimeler

Polikistik over sendromu, infertilite, GnRH antagonist

Kaynakça

• Burt Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 2012;77(4):332-7.
• Luo S, Li S, Li X, Bai Y, Jin S. Effect of gonadotropin-releasing hormone antagonists on intrauterine insemination cycles in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2014;30(4):255-9.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25
• World Health Organization. WHO Laboratory Manual for the Examination of Human Semen and Sperm-cervical Mucus Interaction, 4th ed. Cambridge: Cambridge University Press; 1999. P 60.
• Sheehan MT. Polycystic ovarian syndrome: diagnosis and management. Clin Med Res. 2004;2(1):13-27.
• Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14(4):367-78.
• Futterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Surv. 1999;54(6):403-13.
• Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83(7):2361-5.
• Homburg R. The management of infertility associated with polycystic ovary syndrome. Reprod Biol Endocrinol. 2003;14(1):109.
• Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update. 1999;5(5):493-9.
• Williams RS, Hillard JB, De Vane G, Yeko T, Kipersztok S, Rhoton-Vlasak A, Sistrom C.l. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy. Am J Obstet Gynecol. 2004;191(2):648-51.
• Gomez-Palomares JL, Julia B, Acevedo-Martin B, Martinez- Burgos M, Hernandez ER, Ricciarelli E. Timing ovulation for intrauterine insemination with a GnRH antagonist. Hum Reprod. 2005;20(2):368-72.
• Hossein Rashidi B, Behrouzi Lak T, ShahrokhTehrani E, Davari Tanha F. Fixed versus Flexible Gonadotropin Releasing Hormone Antagonist Protocol in Controlled Ovarian Stimulation for Invitro Fertilization in Women with Polycystic Ovary Syndrome. Journal of Family & Reproductive Health. 2015;9(3):141-6.
• Lubin V, Charbonnel B, Bouchard P. The use of gonadotrophin-releasin-g polycystic ovarian disease. Baillieres Clin Obstet Gynaecol. 1998;12(4):607-18. hormone antagonists in
• Ron-El R, Raziel A, Schachter M, Strassburger D, Kasterstein E, Friedler S. Induction of ovulation after GnRH antagonists. Hum Reprod Update 2000;6(4):318–21.
• Ragni G, Alagna F, Brigante C, Riccaboni A, Colombo M, Somigliana E, Crosignani PG. GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages. Hum Reprod. 2004;19(1):54-8.
• Cristello F, Cela V, Artini PG, Genazzani AR. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(6):340-52.
• Rosenwaks Z, Chung PH. High-order multiple pregnancy: is it a matter of inaction or a consequence of practice patterns? Fertil Steril. 2003;79(1):25-6.
• Elkind-Hirsch KE, Webster BW, Brown CP, Vernon MW. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2003;79(3):603-7.
• Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online. 2005;10(5):567-70.
• Garcia-Velasco JA, Isaza V, Vidal C, Landazabal A, Remohi J, Simon C, Pellicer A. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod. 2001;16(12):2533-9.
• Lambalk CB, Leader A, Olivennes F, Fluker MR, Andersen AN, Ingerslev J, Khalaf Y, Avril C, Belaisch-Allart J, Roulier R, Mannaerts B. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double- blind, placebo-controlled, multicentre trial. Hum Reprod. 2006;21(3):632-9.